Microglial Cell Co-Culture and CD11b Agonists for Synaptic Rescue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The role of microglial cells in human neurodevelopmental disorders, particularly Autism Spectrum Disorder (ASD), is largely unexplored, and existing treatments do not effectively address neuronal defects caused by abnormal gene expression, such as in Rett Syndrome.
Innovation Solution
Generation of microglial cells (MGL) from induced pluripotent stem cells (iPSCs) and their use in co-culture systems to enhance synaptic and neuronal activity, combined with the administration of CD11b agonists like ADH-503 to rescue neuronal defects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microglial cells are used to treat neurodevelopmental disorders, then synaptic formation and neuronal activity are enhanced, but the mechanism of action and therapeutic efficacy in human disorders remain unexplored and undefined
Solution Approach 1:
The patent uses CD11b agonists as intermediary substances to mediate the interaction between microglial cells and neurons. The agonist binds to CD11b receptors on microglial cells, activating them to perform therapeutic functions such as synaptic pruning and neuroprotection, thereby enabling treatment while the molecular mechanism is being elucidated
Solution Approach 2:
The patent changes the activation state parameter of microglial cells by administering CD11b agonists. This parameter change activates previously dormant or dysfunctional microglial cells in neurodevelopmental disorders, enabling them to perform their protective and developmental functions without requiring complete understanding of all underlying mechanisms
2Productivity
If CD11b agonists are administered to rescue neuronal defects, then synaptic defects are rescued and disease progression is improved, but the long-term effects and optimal treatment protocols are not yet established
Solution Approach 1:
The patent applies CD11b agonists during critical periods of neurodevelopment before severe neuronal damage occurs. By acting preliminarily during window periods when the brain is still plastic and responsive, the treatment achieves better outcomes with potentially shorter duration, as prevention is more effective than long-term management of established damage
Solution Approach 2:
The patent employs periodic or pulsed administration of CD11b agonists rather than continuous treatment. This periodic action allows the brain to respond to bursts of microglial activation while avoiding potential side effects of chronic stimulation, and may be tailored to specific developmental windows or disease stages
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MGL co-culture systems and CD11b agonists promote synaptic formation and rescue synaptic defects in neuronal cells, improving disease progression and survival in models of Rett Syndrome and other disorders.
Implementation Method 1
The addition of MGL to the BCO enhanced the expression of synaptic and neuronal activity genes, and also genes related to synaptic pruning and microglial signaling
Implementation Method 2
The subject has a deficit in normal phagocytosis and wherein the iPSCs are treated with a CD11b agonist prior to and concurrently with differentiation to microglial cells
Data Source
AI summary
The disclosure provides methods and compositions related to microglial cell development and therapies in neuronal development.